Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
ISR's Cash to Debt is ranked higher than
92% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.21 vs. ISR: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ISR' s 10-Year Cash to Debt Range
Min: 0.05  Med: 9999.00 Max: No Debt
Current: No Debt
Equity to Asset 0.92
ISR's Equity to Asset is ranked higher than
96% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. ISR: 0.92 )
Ranked among companies with meaningful Equity to Asset only.
ISR' s 10-Year Equity to Asset Range
Min: -1.18  Med: 0.81 Max: 0.92
Current: 0.92
-1.18
0.92
F-Score: 3
Z-Score: 20.06
M-Score: 2.17
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -107.97
ISR's Operating margin (%) is ranked lower than
89% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.48 vs. ISR: -107.97 )
Ranked among companies with meaningful Operating margin (%) only.
ISR' s 10-Year Operating margin (%) Range
Min: -360.83  Med: -89.88 Max: -10.59
Current: -107.97
-360.83
-10.59
Net-margin (%) -102.59
ISR's Net-margin (%) is ranked lower than
88% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.54 vs. ISR: -102.59 )
Ranked among companies with meaningful Net-margin (%) only.
ISR' s 10-Year Net-margin (%) Range
Min: -412.14  Med: -85.24 Max: -12.01
Current: -102.59
-412.14
-12.01
ROE (%) -18.64
ISR's ROE (%) is ranked lower than
75% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.29 vs. ISR: -18.64 )
Ranked among companies with meaningful ROE (%) only.
ISR' s 10-Year ROE (%) Range
Min: -659.02  Med: -50.05 Max: -44.47
Current: -18.64
-659.02
-44.47
ROA (%) -16.97
ISR's ROA (%) is ranked lower than
78% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.43 vs. ISR: -16.97 )
Ranked among companies with meaningful ROA (%) only.
ISR' s 10-Year ROA (%) Range
Min: -6600  Med: -41.34 Max: 23500
Current: -16.97
-6600
23500
ROC (Joel Greenblatt) (%) -81.95
ISR's ROC (Joel Greenblatt) (%) is ranked lower than
81% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.56 vs. ISR: -81.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ISR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -917.05  Med: -100.98 Max: -6.64
Current: -81.95
-917.05
-6.64
Revenue Growth (3Y)(%) -21.90
ISR's Revenue Growth (3Y)(%) is ranked lower than
91% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. ISR: -21.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ISR' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -50.00 Max: 12.2
Current: -21.9
0
12.2
EBITDA Growth (3Y)(%) 14.50
ISR's EBITDA Growth (3Y)(%) is ranked higher than
64% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.70 vs. ISR: 14.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ISR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -26.60 Max: 205.5
Current: 14.5
0
205.5
EPS Growth (3Y)(%) 13.30
ISR's EPS Growth (3Y)(%) is ranked higher than
60% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. ISR: 13.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ISR' s 10-Year EPS Growth (3Y)(%) Range
Min: -67.8  Med: -28.60 Max: 233.2
Current: 13.3
-67.8
233.2
» ISR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ISR Guru Trades in Q3 2014

Jeff Auxier 14,218 sh (unchged)
» More
Q4 2014

ISR Guru Trades in Q4 2014

Jeff Auxier 14,218 sh (unchged)
» More
Q1 2015

ISR Guru Trades in Q1 2015

Jeff Auxier 14,218 sh (unchged)
» More
Q2 2015

ISR Guru Trades in Q2 2015

Jeff Auxier 14,218 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ISR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 21.01
ISR's Forward P/E is ranked higher than
53% of the 75 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.74 vs. ISR: 21.01 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 3.66
ISR's P/B is ranked lower than
59% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.91 vs. ISR: 3.66 )
Ranked among companies with meaningful P/B only.
ISR' s 10-Year P/B Range
Min: 0.31  Med: 3.77 Max: 77
Current: 3.66
0.31
77
P/S 17.88
ISR's P/S is ranked lower than
94% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. ISR: 17.88 )
Ranked among companies with meaningful P/S only.
ISR' s 10-Year P/S Range
Min: 0.56  Med: 5.38 Max: 285
Current: 17.88
0.56
285
Current Ratio 13.49
ISR's Current Ratio is ranked higher than
97% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.41 vs. ISR: 13.49 )
Ranked among companies with meaningful Current Ratio only.
ISR' s 10-Year Current Ratio Range
Min: 0.82  Med: 6.53 Max: 24.59
Current: 13.49
0.82
24.59
Quick Ratio 12.97
ISR's Quick Ratio is ranked higher than
97% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.60 vs. ISR: 12.97 )
Ranked among companies with meaningful Quick Ratio only.
ISR' s 10-Year Quick Ratio Range
Min: 0.68  Med: 5.70 Max: 24.21
Current: 12.97
0.68
24.21
Days Inventory 33.76
ISR's Days Inventory is ranked higher than
92% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 128.59 vs. ISR: 33.76 )
Ranked among companies with meaningful Days Inventory only.
ISR' s 10-Year Days Inventory Range
Min: 2.2  Med: 39.96 Max: 64.02
Current: 33.76
2.2
64.02
Days Sales Outstanding 89.86
ISR's Days Sales Outstanding is ranked lower than
80% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 63.01 vs. ISR: 89.86 )
Ranked among companies with meaningful Days Sales Outstanding only.
ISR' s 10-Year Days Sales Outstanding Range
Min: 0.98  Med: 61.87 Max: 109.1
Current: 89.86
0.98
109.1

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 7.94
ISR's Price/Net Current Asset Value is ranked higher than
50% of the 112 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.89 vs. ISR: 7.94 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ISR' s 10-Year Price/Net Current Asset Value Range
Min: 0.71  Med: 6.38 Max: 175
Current: 7.94
0.71
175
Price/Tangible Book 3.67
ISR's Price/Tangible Book is ranked higher than
57% of the 157 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.27 vs. ISR: 3.67 )
Ranked among companies with meaningful Price/Tangible Book only.
ISR' s 10-Year Price/Tangible Book Range
Min: 0.35  Med: 3.84 Max: 72.5
Current: 3.67
0.35
72.5
Price/Median PS Value 3.33
ISR's Price/Median PS Value is ranked lower than
99% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. ISR: 3.33 )
Ranked among companies with meaningful Price/Median PS Value only.
ISR' s 10-Year Price/Median PS Value Range
Min: 0.12  Med: 1.04 Max: 46.36
Current: 3.33
0.12
46.36
Earnings Yield (Greenblatt) (%) -5.56
ISR's Earnings Yield (Greenblatt) (%) is ranked lower than
78% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. ISR: -5.56 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ISR' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -5.56  Med: 317.80 Max: 16057.5
Current: -5.56
-5.56
16057.5

Analyst Estimate

Jun15 Jun16 Jun17 Jun18
Revenue(Mil) 6 14 22 31
EPS($) -0.04 0.07 0.17 0.26
EPS without NRI($) -0.04 0.07 0.17 0.26

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
IsoRay Inc was organized under Minnesota law in 1983. The Company develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. In 2003, the Company obtained clearance from the FDA for treatment for all solid tumor applications using Cesium-131. Such applications include prostate cancer; ocular melanoma; head, neck and lung tumors; breast cancer; liver cancer; brain cancer; colorectal cancer; gynecological cancer; esophageal cancer; and pancreatic cancer. The brachytherapy seed form of Cesium-131 may be used in surface, interstitial and intracavity applications for tumors with known radio sensitivity. In March 2011, the Company received clearance to commercially deliver Proxcelan Cesium-131 brachytherapy seeds that are preloaded into bioabsorbable braided strands into Europe. Its products include Proxcelan Cesium-131, GliaSite RTS is the only FDA cleared balloon catheter device used in the treatment of brain cancer. The GliaSite RTS and the Company's brachytherapy products used in non-prostate applications typically compete with external beam radiation therapy (EBRT), which can be provided as conventional or intensity modulated radiation therapy, or as stereotactic radiosurgery, a technique that delivers high doses of radiation to a target in a much lower number of sessions than other forms of EBRT. The Company's present and future activities in the development, manufacture and sale of cancer therapy products are subject to extensive laws, regulations, regulatory approvals and guidelines.
» More Articles for ISR

Headlines

Articles On GuruFocus.com
Isoray, Inc. Announces Appointment of PCG Advisory Group as Investor, Public and Digital Communicati Aug 10 2015 
IsoRay's Cesium-131 Cancer Fighting Portfolio was on Display at the American Association of Physicis Jul 16 2015 
IsoRay's Cesium-131 Selected by Chicago Prostate Cancer Center for Use in the Launch of a Study of t Jun 29 2015 
IsoRay's Cancer Fighting Isotope Cesium-131 Will Be Featured in Four Oral Presentations at the Ameri Apr 08 2015 
ciazek stock Mar 28 2015 
UPMC Study Reports IsoRay's Cesium-131 Prostate Treatment Provides Strong Cancer Control With Lower Jan 20 2015 
IsoRay's Cesium-131 Therapy Takes Center Stage at Russia's Neftyanik Hospital a Center of Excellence Jan 13 2015 
IsoRay Ranked 5th Highest Share Price Percentage Gainer (192%) in 2014 Among 2417 Companies Listed o Jan 12 2015 
IsoRay's Cesium-131 Used in World's First Veterinary Implant in a Horse With Cancer Dec 08 2014 
IsoRay Inc. Reports Operating Results (10-K) Sep 28 2010 

More From Other Websites
Isoray, Inc. Announces Appointment of PCG Advisory Group as Investor, Public and Digital... Aug 10 2015
IMPORTANT INVESTOR ALERT: Goldberg Law PC Reminds Investors With Losses in IsoRay, Inc. of July 21,... Jul 17 2015
ISORAY SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of... Jul 17 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of IsoRay, Inc. of Pendency of Class... Jul 17 2015
Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of the Upcoming Deadline in the... Jul 16 2015
IsoRay's Cesium-131 Cancer Fighting Portfolio was on Display at the American Association of... Jul 16 2015
IMPORTANT ANNOUNCEMENT ABOUT IMPENDING LEAD PLAINTIFF DEADLINE: Wolf Haldenstein Adler Freeman &... Jul 15 2015
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Class Action Involving... Jul 15 2015
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in... Jul 13 2015
Glancy Prongay & Murray LLP Reminds Investors Of The Upcoming Deadline In The Class Action Filed On... Jul 10 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of IsoRay, Inc. of Pendency of Class... Jul 09 2015
Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against... Jul 06 2015
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against IsoRay,... Jul 03 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of IsoRay, Inc. of Pendency of Class... Jul 01 2015
IsoRay Investors Alert: Lieff Cabraser Reminds Investors of July 21, 2015 Deadline in Class Action... Jun 30 2015
IsoRay's Cesium-131 Selected by Chicago Prostate Cancer Center for Use in the Launch of a Study of... Jun 29 2015
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims Against IsoRay, Inc.... Jun 26 2015
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in... Jun 26 2015
SECURITIES ALERT: The Rosen Law Firm Reminds IsoRay, Inc. Investors of the Important Deadline in the... Jun 26 2015
IsoRay Intends to Vigorously Defend Litigation Jun 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK